세계의 의료 시뮬레이션 시장 예측(-2030년) : 제품·서비스별, 기술별, 최종사용자별, 지역별

The global healthcare simulation market is projected to reach USD 7.23 billion by 2030 from USD 3.5 billion in 2025, at a CAGR of 15.6%. Key drivers of the healthcare simulation market include the global shift toward competency-based medical education (CBME), increasing emphasis on patient safety, and rapid technological advancements such as AI-powered simulators and VR/AR-based platforms. The growing need for specialty-specific training and remote learning solutions further supports market growth. However, major restraints include the high capital and operational costs associated with simulation infrastructure and limited accessibility in low-resource settings. Additionally, the lack of standardization across simulation practices poses challenges in ensuring consistent training quality.

"Web-based simulation segment to witness highest CAGR during forecast period"

Based on the product & service segment, the healthcare simulation market is classified into healthcare simulation anatomical models, healthcare simulation software, web-based simulation, and healthcare simulation training services. Among these, web-based simulation is expected to grow the fastest during the forecast period due to its scalability, flexibility, and cost-efficiency, qualities ideal for academic and healthcare settings. Its adoption has accelerated with the global shift to remote and hybrid learning models, especially post-COVID-19. Unlike hardware-based tools, web-based platforms require minimal infrastructure, making them suitable for resource-constrained environments. These platforms also enable real-time performance tracking, customizable scenarios, and multi-user collaboration, enhancing training outcomes. Furthermore, the integration of cloud computing, AI, and data analytics enables personalized learning and robust assessment. Solutions such as Laerdal's vSim, CAE Healthcare's LearningSpace, and Oxford Medical Simulation exemplify the global momentum in this space. This trend reduces dependence on physical labs while expanding access, fueling the segment's rapid growth.

"Procedural rehearsal technology held largest share of healthcare simulation market in 2024"

The procedural rehearsal technology segment accounted for the largest share of the healthcare simulation market in 2024 because it directly addresses the critical need for hands-on practice for complex medical procedures. This technology enables clinicians and surgeons to rehearse specific surgeries or interventions on highly realistic models, often patient-specific, improving precision and reducing errors during actual procedures. Its widespread adoption is driven by increasing demand for minimally invasive surgeries, growing emphasis on reducing surgical complications, and rising investments in advanced imaging and 3D modeling technologies. Procedural rehearsal technology bridges the gap between theoretical knowledge and real-world application, making it indispensable in medical training and preoperative planning.

"Asia Pacific region to exhibit significant CAGR from 2025 to 2030"

The Asia Pacific region is projected to record the highest CAGR in the global healthcare simulation market during the forecast period. This growth is fueled by a rise in surgical procedures, increasing the need for procedural rehearsal tools, anatomical models, and high-fidelity simulators to ensure safe and effective clinical training. Countries such as China, India, and those in Southeast Asia are investing heavily in healthcare infrastructure and upgrading medical education through simulation technologies. Expansion in this high-potential, underpenetrated market is also supported by greater government funding, global partnerships, and the growing entry of international simulation providers. For example, in April 2022, the Delhi Academy of Medical Sciences (DAMS) launched a simulation-based education facility, allowing medical students to safely practice clinical procedures without risk to real patients.

In-depth interviews have been conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the authentication and brand protection marketplace.

The breakdown of primary participants is as mentioned below:

• By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
• By Designation - C-level Executives: 42%, Directors: 31%, and Others: 27%
• By Region - North America: 32%, Europe: 32%, Asia Pacific: 26%, Middle East & Africa: 5%, and Latin America: 5%

Note: Other designations include sales, marketing, and product managers.

Tiers are defined based on a company's total revenue as of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

Key Players in Healthcare Simulation Market

The key players functioning in the healthcare simulation market include CAE Inc. (Canada), Laerdal Medical (Norway), Gaumard Scientific Co. (US), Kyoto Kagaku (Japan), Limbs & Things (UK), Mentice AB (Sweden), Simulab Corporation (US), Simulaids (US), Intelligent Ultrasound Group PLC (UK), Operative Experience Inc. (UK), Surgical Science Sweden AB (Sweden), Cardionics Inc. (US), VirtaMed AG (Zurich), SYNBONE AG (Switzerland), IngMar Medical (US), Medical-X (Netherlands), KaVo Dental GmbH (Germany), Altay Scientific (Italy), TruCorp Ltd. (Ireland), Simendo B.V. (Netherlands), Haag-Streit Simulation GmbH (Germany), Symgery (Canada), HRV Simulation (France), Synaptive Medical (Canada), and Inovus Medical (UK).

Research Coverage:

The report analyzes the healthcare simulation market. It aims to estimate the market size and future growth potential of various market segments based on product & service, technology, end user, and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will help established firms and new entrants/smaller firms gauge the market's pulse, which, in turn, would help them garner a larger market share. Firms purchasing the report could use one or a combination of the strategies mentioned below to strengthen their positions in the market.

This report provides insights on:

• Analysis of key drivers: (rising focus on patient safety, rising shift toward competency-based medical education (CBME)), restraints (high setup and operational costs, limited access in low-resource settings), opportunities (growing demand for web-based and remote simulation products and services, rising use of specialty-specific simulation techniques by healthcare professionals), and challenges (lack of standardization in training protocols, limited emotional realism in some tools) influencing the growth of the healthcare simulation market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product & service launches in the healthcare simulation market
• Market Development: Comprehensive information on the lucrative emerging markets, products & services, technologies, end users, and regions
• Market Diversification: Exhaustive information about the product portfolios, untapped geographies, recent developments, and investments in the healthcare simulation market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the healthcare simulation market such as CAE Inc. (Canada), Laerdal Medical (Norway), Gaumard Scientific Co. (US), Kyoto Kagaku (Japan), Limbs & Things (UK), Mentice AB (Sweden), Simulab Corporation (US), and Simulaids (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 STUDY SCOPE
  • 1.2.2 INCLUSIONS AND EXCLUSIONS
  • 1.2.3 YEARS CONSIDERED
• 1.3 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH APPROACH
  • 2.1.1 SECONDARY RESEARCH
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Insights from primary experts
• 2.2 MARKET SIZE ESTIMATION: HEALTHCARE SIMULATION MARKET
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN HEALTHCARE SIMULATION MARKET
• 4.2 HEALTHCARE SIMULATION MARKET IN ASIA PACIFIC, BY PRODUCT & SERVICE AND COUNTRY
• 4.3 HEALTHCARE SIMULATION MARKET, BY GEOGRAPHY
• 4.4 HEALTHCARE SIMULATION MARKET, BY REGION
• 4.5 HEALTHCARE SIMULATION MARKET: EMERGING VS. DEVELOPED ECONOMIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
• 5.3 MARKET DYNAMICS: IMPACT ANALYSIS
  • 5.3.1 DRIVERS
    • 5.3.1.1 Rising demand for realistic and risk-free training environments in medical education
    • 5.3.1.2 Rapid technological advancements in medical education
    • 5.3.1.3 Surging demand for minimally invasive treatments
    • 5.3.1.4 Increasing focus on patient safety
    • 5.3.1.5 Growing adoption of AI-driven VR platforms to improve clinical decision-making
  • 5.3.2 RESTRAINTS
    • 5.3.2.1 Limited availability of funds to establish simulation training centers
    • 5.3.2.2 Poorly designed medical simulators
  • 5.3.3 OPPORTUNITIES
    • 5.3.3.1 Widening workforce gaps creating demand for simulation-based training solutions
    • 5.3.3.2 Growing awareness about simulation training in emerging economies
  • 5.3.4 CHALLENGES
    • 5.3.4.1 High cost of simulators
    • 5.3.4.2 Operational challenges
• 5.4 INDUSTRY TRENDS
  • 5.4.1 USE OF VIRTUAL REALITY AND AUGMENTED REALITY IN HEALTHCARE SIMULATION
  • 5.4.2 ADVANCEMENTS IN HIGH-FIDELITY TECHNOLOGY
  • 5.4.3 ADOPTION OF MULTIMODAL APPROACH DURING SIMULATOR DEVELOPMENT
  • 5.4.4 UTILIZATION OF AI- AND ML-BASED SOFTWARE IN SURGICAL PROCEDURES
  • 5.4.5 INCLINATION TOWARD HEALTHCARE INFORMATION TECHNOLOGY/ELECTRONIC MEDICAL RECORDS
• 5.5 TECHNOLOGY ANALYSIS
  • 5.5.1 KEY TECHNOLOGIES
  • 5.5.2 ADJACENT TECHNOLOGIES
  • 5.5.3 ARTIFICIAL INTELLIGENCE AND VIRTUAL REALITY
• 5.6 ECOSYSTEM ANALYSIS
• 5.7 VALUE CHAIN ANALYSIS
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • 5.8.1 THREAT OF NEW ENTRANTS
  • 5.8.2 THREAT OF SUBSTITUTES
  • 5.8.3 BARGAINING POWER OF SUPPLIERS
  • 5.8.4 BARGAINING POWER OF BUYERS
  • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.9 PATENT ANALYSIS
  • 5.9.1 PATENT PUBLICATION TRENDS IN HEALTHCARE SIMULATION MARKET
  • 5.9.2 JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.9.3 LIST OF MAJOR PATENTS
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10.2 GLOBAL REGULATORY STANDARDS
  • 5.10.3 HEALTHCARE SIMULATION PRODUCTS REQUIRING PREMARKET APPROVALS FROM REGULATORY BODIES
    • 5.10.3.1 North America
      • 5.10.3.1.1 US
      • 5.10.3.1.2 Canada
    • 5.10.3.2 Europe
    • 5.10.3.3 Asia Pacific
      • 5.10.3.3.1 Japan
      • 5.10.3.3.2 China
      • 5.10.3.3.3 India
  • 5.10.4 INTEROPERABILITY STANDARDS
• 5.11 PRICING ANALYSIS
  • 5.11.1 INDICATIVE PRICE OF HEALTHCARE SIMULATION PRODUCTS, BY KEY PLAYERS 2024
  • 5.11.2 INDICATIVE PRICE OF HEALTHCARE SIMULATION DEVICES, BY REGION 2024
• 5.12 HEALTHCARE SIMULATION MARKET: INVESTMENT LANDSCAPE
• 5.13 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.15.2 BUYING CRITERIA
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 CASE STUDY 1: ENHANCING CLINICAL READINESS: NORTHUMBRIA UNIVERSITY'S SCALABLE SIMULATION PROGRAM IN PARTNERSHIP WITH OMB
  • 5.16.2 CASE STUDY 2: OPTIMIZING PATIENT FLOW AND INFRASTRUCTURE: MEMORIAL HEALTH SYSTEM'S SIMULATION-DRIVEN EFFICIENCY GAINS WITH SIMUL8
• 5.17 UNMET NEEDS IN HEALTHCARE SIMULATION MARKET
  • 5.17.1 EXPECTATIONS OF END USERS
• 5.18 IMPACT OF 2025 US TARIFF-OVERVIEW
  • 5.18.1 INTRODUCTION
• 5.19 KEY TARIFF RATES
• 5.20 PRICE IMPACT ANALYSIS
• 5.21 IMPACT ON COUNTRIES/REGIONS
  • 5.21.1 US
  • 5.21.2 EUROPE
  • 5.21.3 ASIA PACIFIC
• 5.22 IMPACT ON END USERS

6 HEALTHCARE SIMULATION MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 HEALTHCARE SIMULATION ANATOMICAL MODELS
  • 6.2.1 PATIENT SIMULATORS
    • 6.2.1.1 By type
      • 6.2.1.1.1 High-fidelity simulators
        • 6.2.1.1.1.1 Growing adoption of high-fidelity simulators in educational training to drive growth
      • 6.2.1.1.2 Medium-fidelity simulators
        • 6.2.1.1.2.1 Cost benefits of medium-fidelity simulation to drive demand
      • 6.2.1.1.3 Low-fidelity simulators
        • 6.2.1.1.3.1 Budgetary constraints and ease of use to drive demand
    • 6.2.1.2 By application
      • 6.2.1.2.1 Laparoscopic surgical simulators
        • 6.2.1.2.1.1 Increasing prevalence of minimally invasive surgeries to drive growth
      • 6.2.1.2.2 Gynecology simulators
        • 6.2.1.2.2.1 Increasing incidence of fibroids and polyps in women to drive demand
      • 6.2.1.2.3 Cardiovascular simulators
        • 6.2.1.2.3.1 Increasing prevalence of diabetes to boost demand
      • 6.2.1.2.4 Orthopedic surgical simulators
        • 6.2.1.2.4.1 Enhancement in surgeon skills by orthopedic simulation training to drive demand
      • 6.2.1.2.5 Spine surgical simulators
        • 6.2.1.2.5.1 Mastering spine surgeries through advanced simulation techniques to boost demand
      • 6.2.1.2.6 Endovascular simulators
        • 6.2.1.2.6.1 Reduced mortality rates associated with endovascular simulators to boost demand
      • 6.2.1.2.7 Other applications in patient simulators
  • 6.2.2 TASK TRAINERS
    • 6.2.2.1 Inability to imitate emotional attributes of patients to restrain growth
  • 6.2.3 INTERVENTIONAL/SURGICAL SIMULATORS
    • 6.2.3.1 Laparoscopic surgical simulators
      • 6.2.3.1.1 Increasing preference for minimally invasive surgeries to drive growth
    • 6.2.3.2 Gynecology simulators
      • 6.2.3.2.1 Increasing incidence of fibroids and polyps in women to drive demand for gynecology simulators
    • 6.2.3.3 Cardiovascular simulators
      • 6.2.3.3.1 Increasing prevalence of obesity and diabetes to boost demand
    • 6.2.3.4 Orthopedic surgical simulators
      • 6.2.3.4.1 Enhancement in surgeon skills by orthopedic simulation training to drive demand
    • 6.2.3.5 Spine surgical simulators
      • 6.2.3.5.1 Mastering spine surgeries through advanced simulation techniques to boost demand
    • 6.2.3.6 Endovascular simulators
      • 6.2.3.6.1 Ability to reduce mortality rates to drive demand for endovascular simulators
    • 6.2.3.7 Other surgical simulators
  • 6.2.4 ULTRASOUND SIMULATORS
    • 6.2.4.1 Inferior quality images due to low dynamics and spatial resolution to restrain growth
  • 6.2.5 DENTAL SIMULATORS
    • 6.2.5.1 Expanding dental tourism industry to drive growth
  • 6.2.6 EYE SIMULATORS
    • 6.2.6.1 Increasing incidence of eye disorders to drive growth
• 6.3 WEB-BASED SIMULATION
  • 6.3.1 RISING TECHNOLOGICAL ADVANCEMENTS TO DRIVE ADOPTION OF WEB-BASED SIMULATION
• 6.4 HEALTHCARE SIMULATION SOFTWARE
  • 6.4.1 ABILITY TO REDUCE OVERALL SURGICAL PROCESS TRAINING TIME TO DRIVE ADOPTION
• 6.5 HEALTHCARE SIMULATION TRAINING SERVICES
  • 6.5.1 VENDOR-BASED TRAINING
    • 6.5.1.1 High focus on patient safety to drive demand
  • 6.5.2 EDUCATIONAL SOCIETIES
    • 6.5.2.1 Growing need for proper training and authenticity of knowledge to drive growth
  • 6.5.3 CUSTOM CONSULTING SERVICES
    • 6.5.3.1 Growing need to limit errors associated with traditional medical training systems to drive growth

7 HEALTHCARE SIMULATION MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 VIRTUAL PATIENT SIMULATION
  • 7.2.1 INCREASING FOCUS ON AUGMENTED REALITY/VIRTUAL REALITY TO DRIVE MARKET
• 7.3 3D PRINTING
  • 7.3.1 INCREASING ADOPTION IN MEDICAL TRAINING TO DRIVE MARKET
• 7.4 PROCEDURAL REHEARSAL TECHNOLOGY
  • 7.4.1 NEED FOR ADVANCING SURGICAL SKILLS WITH REHEARSAL TECH TO FUEL MARKET GROWTH

8 HEALTHCARE SIMULATION MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 ACADEMIC INSTITUTES
  • 8.2.1 GROWING NEED FOR SKILLED MEDICAL PROFESSIONALS TO DRIVE DEMAND
• 8.3 HOSPITALS
  • 8.3.1 RISING FOCUS ON MINIMIZING MEDICAL ERRORS TO DRIVE DEMAND
• 8.4 MILITARY ORGANIZATIONS
  • 8.4.1 EXPLORATION OF NEW METHODS OF MEDICAL CARE DURING WARFARE TO DRIVE DEMAND
• 8.5 OTHER END USERS

9 HEALTHCARE SIMULATION MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 9.2.2 US
    • 9.2.2.1 Increasing demand for virtual tutors and high healthcare spending to boost growth
  • 9.2.3 CANADA
    • 9.2.3.1 Increasing funding and surgical capabilities to drive growth
• 9.3 EUROPE
  • 9.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 9.3.2 UK
    • 9.3.2.1 Rising number of healthcare simulation centers and hospitals to drive growth
  • 9.3.3 FRANCE
    • 9.3.3.1 Growing focus on use of innovative methods in medical training to drive growth
  • 9.3.4 GERMANY
    • 9.3.4.1 High healthcare spending to drive market growth
  • 9.3.5 ITALY
    • 9.3.5.1 Shortage of trained healthcare personnel to drive growth
  • 9.3.6 SPAIN
    • 9.3.6.1 Increasing number of surgical procedures to boost growth
  • 9.3.7 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 9.4.2 JAPAN
    • 9.4.2.1 Increasing demand for virtual tutors and technologically advanced simulators to drive growth
  • 9.4.3 CHINA
    • 9.4.3.1 Increasing demand for trained medical professionals to drive growth
  • 9.4.4 INDIA
    • 9.4.4.1 Growing awareness regarding patient safety due to healthcare negligence to drive growth
  • 9.4.5 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 9.5.2 BRAZIL
    • 9.5.2.1 High incidence of chronic diseases to drive market
  • 9.5.3 MEXICO
    • 9.5.3.1 Disruptive technologies and public-private partnerships to boost growth
  • 9.5.4 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • 9.6.2 GCC
    • 9.6.2.1 Focus on enhancing patient care to drive market
  • 9.6.3 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022-2025
• 10.3 REVENUE ANALYSIS, 2020-2024
• 10.4 MARKET SHARE ANALYSIS, 2024
• 10.5 MARKET RANKING ANALYSIS, 2024
• 10.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 10.6.1 STARS
  • 10.6.2 EMERGING LEADERS
  • 10.6.3 PERVASIVE PLAYERS
  • 10.6.4 PARTICIPANTS
  • 10.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 10.6.5.1 Company footprint
    • 10.6.5.2 Region footprint
    • 10.6.5.3 Product & service footprint
    • 10.6.5.4 End user footprint
    • 10.6.5.5 Technology footprint
• 10.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 10.7.1 PROGRESSIVE COMPANIES
  • 10.7.2 RESPONSIVE COMPANIES
  • 10.7.3 DYNAMIC COMPANIES
  • 10.7.4 STARTING BLOCKS
  • 10.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 10.7.5.1 Detailed list of key startups/SMEs
    • 10.7.5.2 Competitive benchmarking of key startups/SMEs
• 10.8 BRAND/SOFTWARE COMPARISON
• 10.9 COMPETITIVE SCENARIO
  • 10.9.1 PRODUCT LAUNCHES/ENHANCEMENTS
  • 10.9.2 PRODUCT LAUNCHES/ENHANCEMENTS
  • 10.9.3 DEALS
  • 10.9.4 OTHER DEVELOPMENTS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 SURGICAL SCIENCE SWEDEN AB
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Deals
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Key strengths
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses and competitive threats
  • 11.1.2 LAERDAL MEDICAL
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Product launches/enhancements
      • 11.1.2.3.2 Deals
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Key strengths
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses and competitive threats
  • 11.1.3 GAUMARD SCIENTIFIC
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Product launches/enhancements
      • 11.1.3.3.2 Deals
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Key strengths
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses and competitive threats
  • 11.1.4 KYOTO KAGAKU CO., LTD.
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products offered
    • 11.1.4.3 MnM view
      • 11.1.4.3.1 Key strengths
      • 11.1.4.3.2 Strategic choices
      • 11.1.4.3.3 Weaknesses and competitive threats
  • 11.1.5 LIMBS & THINGS LTD
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Product launches/enhancements
      • 11.1.5.3.2 Deals
    • 11.1.5.4 MnM view
      • 11.1.5.4.1 Key strengths
      • 11.1.5.4.2 Strategic choices
      • 11.1.5.4.3 Weaknesses and competitive threats
  • 11.1.6 MENTICE AB
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Product launches/enhancements
      • 11.1.6.3.2 Deals
  • 11.1.7 SIMULAB CORPORATION
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Product launches/enhancements
  • 11.1.8 SIMULAIDS
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Product launches/enhancements
  • 11.1.9 OPERATIVE EXPERIENCE, INC.
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
    • 11.1.9.3 Recent developments
      • 11.1.9.3.1 Developments
  • 11.1.10 NASCO HEALTHCARE
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products offered
    • 11.1.10.3 Recent developments
      • 11.1.10.3.1 Deals
  • 11.1.11 ANATOMAGE
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products offered
    • 11.1.11.3 Recent developments
      • 11.1.11.3.1 Product launches/enhancements
      • 11.1.11.3.2 Other developments
  • 11.1.12 CARDIONICS INC.
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products offered
  • 11.1.13 VIRTAMED AG
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products offered
      • 11.1.13.2.1 Product launches/enhancements
      • 11.1.13.2.2 Deals
  • 11.1.14 SYNBONE AG
    • 11.1.14.1 Business overview
    • 11.1.14.2 Products offered
  • 11.1.15 INGMAR MEDICAL
    • 11.1.15.1 Business overview
    • 11.1.15.2 Products offered
    • 11.1.15.3 Recent developments
      • 11.1.15.3.1 Deals
  • 11.1.16 MEDICAL-X
    • 11.1.16.1 Business overview
    • 11.1.16.2 Products offered
  • 11.1.17 KAVO DENTAL
    • 11.1.17.1 Business overview
    • 11.1.17.2 Products offered
  • 11.1.18 ALTAY SCIENTIFIC
    • 11.1.18.1 Business overview
    • 11.1.18.2 Products offered
  • 11.1.19 TRUCORP LIMITED
    • 11.1.19.1 Business overview
    • 11.1.19.2 Products offered
    • 11.1.19.3 Recent developments
      • 11.1.19.3.1 Product launches/enhancements
      • 11.1.19.3.2 Deals
  • 11.1.20 SIMENDO
    • 11.1.20.1 Business overview
    • 11.1.20.2 Products offered
• 11.2 OTHER PLAYERS
  • 11.2.1 HAAG-STREIT AG
  • 11.2.2 SYMGERY
  • 11.2.3 HRV SIMULATION
  • 11.2.4 SYNAPTIVE MEDICAL
  • 11.2.5 INOVUS LIMITED

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS